{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:32:16Z","timestamp":1793140336031,"version":"4.5.0"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41575-026-01202-y","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T09:19:35Z","timestamp":1776676775000},"page":"655-668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Deciphering cytochrome P450 reductase role in MASLD: molecular mechanisms and pathophysiological implications"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8496-4522","authenticated-orcid":false,"given":"Catarina","family":"Baptista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3046-1313","authenticated-orcid":false,"given":"Francisco","family":"Esteves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-1471","authenticated-orcid":false,"given":"Jonathan A.","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-2786","authenticated-orcid":false,"given":"Timothy J.","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4197-4843","authenticated-orcid":false,"given":"Leonard J.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1362-0076","authenticated-orcid":false,"given":"Michel","family":"Kranendonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"1202_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335\u20131347 (2023).","journal-title":"Hepatology"},{"key":"1202_CR2","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1016\/j.jhep.2023.08.021","volume":"80","author":"L Chen","year":"2023","unstructured":"Chen, L., Tao, X., Zeng, M., Mi, Y. & Xu, L. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. J. Hepatol. 80, e64\u2013e66 (2023).","journal-title":"J. Hepatol."},{"key":"1202_CR3","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.7150\/ijbs.85145","volume":"19","author":"DW Han","year":"2023","unstructured":"Han, D. W. et al. Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases. Int. J. Biol. Sci. 19, 3595\u20133613 (2023).","journal-title":"Int. J. Biol. Sci."},{"key":"1202_CR4","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1073\/pnas.1700172114","volume":"114","author":"X Zhang","year":"2017","unstructured":"Zhang, X. et al. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. Proc. Natl Acad. Sci. USA 114, 3181\u20133185 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1202_CR5","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.3390\/ijerph18105227","volume":"18","author":"O Juanola","year":"2021","unstructured":"Juanola, O., Mart\u00ednez-L\u00f3pez, S., Franc\u00e9s, R. & G\u00f3mez-Hurtado, I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int. J. Environ. Res. Public Health 18, 5227 (2021).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"1202_CR6","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.3390\/ijms22084156","volume":"22","author":"Y Sakurai","year":"2021","unstructured":"Sakurai, Y., Kubota, N., Yamauchi, T. & Kadowaki, T. Role of insulin resistance in MAFLD. Int. J. Mol. Sci. 22, 4156 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1202_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","volume":"10","author":"R Loomba","year":"2013","unstructured":"Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686\u2013690 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1202_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3389\/fmed.2020.00395","volume":"7","author":"I Garcia-Martinez","year":"2020","unstructured":"Garcia-Martinez, I., Alen, R., Rada, P. & Valverde, A. M. Insights into extracellular vesicles as biomarker of NAFLD pathogenesis. Front. Med. 7, 395 (2020).","journal-title":"Front. Med."},{"key":"1202_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41590-024-02037-y","volume":"26","author":"P Zhang","year":"2025","unstructured":"Zhang, P., Watari, K. & Karin, M. Innate immune cells link dietary cues to normal and abnormal metabolic regulation. Nat. Immunol. 26, 29\u201341 (2025).","journal-title":"Nat. Immunol."},{"key":"1202_CR10","doi-asserted-by":"crossref","unstructured":"Fl\u00fcck, C. E. & Pandey, A. V. in Genetic Steroid Disorders (eds New, M. I. et al.) 125\u2013143 (Elsevier, 2014).","DOI":"10.1016\/B978-0-12-416006-4.00010-7"},{"key":"1202_CR11","doi-asserted-by":"crossref","unstructured":"Waskell, L., Kim, J.-J. P. & Kim, J.-J. P. in Cytochrome P450 (ed. Ortiz de Montellano, P. R.) 33\u201368 (Springer, 2015).","DOI":"10.1007\/978-3-319-12108-6_2"},{"key":"1202_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/molecules27144646","volume":"27","author":"M Nurhafizuddin","year":"2022","unstructured":"Nurhafizuddin, M., Azizi, A., Ming, L. C. & Shafqat, N. In silico analysis of PORD mutations on the 3D structure of P450 oxidoreductase. Molecules 27, 46 (2022).","journal-title":"Molecules"},{"key":"1202_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.biochi.2019.04.020","volume":"162","author":"EO Yablokov","year":"2019","unstructured":"Yablokov, E. O. et al. A large-scale comparative analysis of affinity, thermodynamics and functional characteristics of interactions of twelve cytochrome P450 isoforms and their redox partners. Biochimie 162, 156\u2013166 (2019).","journal-title":"Biochimie"},{"key":"1202_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pharmthera.2013.01.010","volume":"138","author":"AV Pandey","year":"2013","unstructured":"Pandey, A. V. & Fl\u00fcck, C. E. NADPH P450 oxidoreductase: structure, function, and pathology of diseases. Pharmacol. Ther. 138, 229\u2013254 (2013).","journal-title":"Pharmacol. Ther."},{"key":"1202_CR15","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s10815-020-01899-z","volume":"37","author":"T Zhang","year":"2020","unstructured":"Zhang, T. et al. Clinical and genetic analysis of cytochrome P450 oxidoreductase (POR) deficiency in a female and the analysis of a novel POR intron mutation causing alternative mRNA splicing. J. Assist. Reprod. Genet. 37, 2503\u20132511 (2020).","journal-title":"J. Assist. Reprod. Genet."},{"key":"1202_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-nutr-071813-105747","volume":"34","author":"D Bishop-Bailey","year":"2014","unstructured":"Bishop-Bailey, D., Thomson, S., Askari, A., Faulkner, A. & Wheeler-Jones, C. Lipid-metabolizing cyps in the regulation and dysregulation of metabolism. Annu. Rev. Nutr. 34, 261\u2013279 (2014).","journal-title":"Annu. Rev. Nutr."},{"key":"1202_CR17","doi-asserted-by":"publisher","first-page":"106407","DOI":"10.1016\/j.prostaglandins.2019.106407","volume":"148","author":"LRBdos Santos","year":"2020","unstructured":"Santos, L. R. B. dos & Fleming, I. Role of cytochrome P450-derived, polyunsaturated fatty acid mediators in diabetes and the metabolic syndrome. Prostaglandins Other Lipid Mediat. 148, 106407 (2020).","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"1202_CR18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1124\/dmd.111.038562","volume":"39","author":"TD Porter","year":"2011","unstructured":"Porter, T. D., Banerjee, S., Stolarczyk, E. I. & Zou, L. Suppression of cytochrome P450 reductase (POR) expression in hepatoma cells replicates the hepatic lipidosis observed in hepatic POR-null mice. Drug Metab. Disposition 39, 966\u2013973 (2011).","journal-title":"Drug Metab. Disposition"},{"key":"1202_CR19","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1440-1681.2011.05622.x","volume":"38","author":"VC Pillai","year":"2011","unstructured":"Pillai, V. C., Snyder, R. O., Gumaste, U., Thekkumkara, T. J. & Mehvar, R. Effects of transient overexpression or knockdown of cytochrome P450 reductase on reactive oxygen species generation and hypoxia reoxygenation injury in liver cells. Clin. Exp. Pharmacol. Physiol. 38, 846\u2013853 (2011).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"1202_CR20","doi-asserted-by":"publisher","first-page":"8221","DOI":"10.3390\/ijms22158221","volume":"22","author":"R Harjum\u00e4ki","year":"2021","unstructured":"Harjum\u00e4ki, R., Pridgeon, C. S. & Ingelman-Sundberg, M. CYP2E1 in alcoholic and non-alcoholic liver injury. Roles of ROS, reactive intermediates and lipid overload. Int. J. Mol. Sci. 22, 8221 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1202_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1124\/dmd.120.000010","volume":"48","author":"T Ashino","year":"2020","unstructured":"Ashino, T., Yamamoto, M. & Numazawa, S. Nrf2 antioxidative system is involved in cytochrome P450 gene expression and activity: a delay in pentobarbital metabolism in nrf2-deficient mice. Drug Metab. Disposition 48, 673\u2013680 (2020).","journal-title":"Drug Metab. Disposition"},{"key":"1202_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s13238-021-00823-0","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula, P., Zhuang, L. & Gan, B. Cytochrome P450 reductase (POR) as a ferroptosis fuel. Protein Cell 12, 675\u2013679 (2021).","journal-title":"Protein Cell"},{"key":"1202_CR23","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41589-020-0472-6","volume":"16","author":"Y Zou","year":"2020","unstructured":"Zou, Y. et al. Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. Nat. Chem. Biol. 16, 302\u2013309 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1202_CR24","doi-asserted-by":"publisher","first-page":"106400","DOI":"10.1016\/j.prostaglandins.2019.106400","volume":"147","author":"SM Shoieb","year":"2020","unstructured":"Shoieb, S. M., El-Ghiaty, M. A., Alqahtani, M. A. & El-Kadi, A. O. S. Cytochrome P450-derived eicosanoids and inflammation in liver diseases. Prostaglandins Other Lipid Mediat. 147, 106400 (2020).","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"1202_CR25","unstructured":"Hardwick, J. P. Cytochrome P450 Function and Pharmacological Roles in Inflammation and Cancer Vol. 74 (Academic, 2015)."},{"key":"1202_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/138920009787522151","volume":"10","author":"B Zordoky","year":"2009","unstructured":"Zordoky, B. & El-Kadi, A. Role of NF-kB in the regulation of cytochrome P450 enzymes. Curr. Drug Metab. 10, 164\u2013178 (2009).","journal-title":"Curr. Drug Metab."},{"key":"1202_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","volume":"23","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 23, 117 (2024).","journal-title":"Lipids Health Dis."},{"key":"1202_CR28","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.molmed.2024.05.013","volume":"30","author":"A Cherubini","year":"2024","unstructured":"Cherubini, A., Della Torre, S., Pelusi, S. & Valenti, L. Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease. Trends Mol. Med. 30, 1126\u20131136 (2024).","journal-title":"Trends Mol. Med."},{"key":"1202_CR29","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1038\/s41591-023-02602-2","volume":"29","author":"TJ Kendall","year":"2023","unstructured":"Kendall, T. J. et al. An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease. Nat. Med. 29, 2939\u20132953 (2023).","journal-title":"Nat. Med."},{"key":"1202_CR30","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","volume":"30","author":"V Raverdy","year":"2024","unstructured":"Raverdy, V. et al. Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat. Med. 30, 3624\u20133633 (2024).","journal-title":"Nat. Med."},{"key":"1202_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/genes16040399","volume":"16","author":"Y Chen","year":"2025","unstructured":"Chen, Y., Bian, S. & Le, J. Molecular landscape and diagnostic model of MASH: transcriptomic, proteomic, metabolomic, and lipidomic perspectives. Genes 16, 399 (2025).","journal-title":"Genes"},{"key":"1202_CR32","doi-asserted-by":"publisher","first-page":"116249","DOI":"10.1016\/j.bcp.2024.116249","volume":"228","author":"O Govaere","year":"2024","unstructured":"Govaere, O. et al. Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment. Biochem. Pharmacol. 228, 116249 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"1202_CR33","doi-asserted-by":"publisher","first-page":"17671","DOI":"10.1038\/srep17671","volume":"5","author":"H Zhang","year":"2015","unstructured":"Zhang, H. et al. Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo. Sci. Rep. 5, 17671 (2015).","journal-title":"Sci. Rep."},{"key":"1202_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41401-022-00924-4","volume":"44","author":"J Wu","year":"2023","unstructured":"Wu, J. et al. Silybin regulates P450s activity by attenuating endoplasmic reticulum stress in mouse nonalcoholic fatty liver disease. Acta Pharmacol. Sin. 44, 133\u2013144 (2023).","journal-title":"Acta Pharmacol. Sin."},{"key":"1202_CR35","doi-asserted-by":"publisher","first-page":"155835","DOI":"10.1016\/j.metabol.2024.155835","volume":"154","author":"M Kokkorakis","year":"2024","unstructured":"Kokkorakis, M. et al. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges. Metabolism 154, 155835 (2024).","journal-title":"Metabolism"},{"key":"1202_CR36","doi-asserted-by":"publisher","first-page":"19790","DOI":"10.1038\/s41598-024-70242-8","volume":"14","author":"R Suvarna","year":"2024","unstructured":"Suvarna, R., Shetty, S. & Pappachan, J. M. Efficacy and safety of resmetirom, a selective thyroid hormone receptor-\u03b2 agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Sci. Rep. 14, 19790 (2024).","journal-title":"Sci. Rep."},{"key":"1202_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fphar.2020.00299","volume":"11","author":"F Esteves","year":"2020","unstructured":"Esteves, F. et al. The role of the FMN-domain of human cytochrome P450 oxidoreductase in its promiscuous interactions with structurally diverse redox partners. Front. Pharmacol. 11, 299 (2020).","journal-title":"Front. Pharmacol."},{"key":"1202_CR38","doi-asserted-by":"publisher","first-page":"25895","DOI":"10.1074\/jbc.M303125200","volume":"278","author":"J Gu","year":"2003","unstructured":"Gu, J. et al. Liver-specific deletion of the NADPH\u2013cytochrome P450 reductase gene. J. Biol. Chem. 278, 25895\u201325901 (2003).","journal-title":"J. Biol. Chem."},{"key":"1202_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41467-017-00049-x","volume":"8","author":"M Barzi","year":"2017","unstructured":"Barzi, M. et al. A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism. Nat. Commun. 8, 39 (2017).","journal-title":"Nat. Commun."},{"key":"1202_CR40","doi-asserted-by":"publisher","first-page":"14907","DOI":"10.1038\/s41598-022-19242-0","volume":"12","author":"S Uehara","year":"2022","unstructured":"Uehara, S. et al. Humanized liver TK-NOG mice with functional deletion of hepatic murine cytochrome P450s as a model for studying human drug metabolism. Sci. Rep. 12, 14907 (2022).","journal-title":"Sci. Rep."},{"key":"1202_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger, U. M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103\u2013141 (2013).","journal-title":"Pharmacol. Ther."},{"key":"1202_CR42","doi-asserted-by":"publisher","unstructured":"Penner, N., Woodward, C. & Prakash, C. in ADME-Enabling Technologies in Drug Design and Development https:\/\/doi.org\/10.1002\/9781118180778.app1 (Wiley, 2012).","DOI":"10.1002\/9781118180778.app1"},{"key":"1202_CR43","doi-asserted-by":"publisher","first-page":"17065","DOI":"10.1074\/jbc.R113.462275","volume":"288","author":"FP Guengerich","year":"2013","unstructured":"Guengerich, F. P. & Munro, A. W. Unusual cytochrome P450 enzymes and reactions. J. Biol. Chem. 288, 17065\u201317073 (2013).","journal-title":"J. Biol. Chem."},{"key":"1202_CR44","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bbagen.2006.07.003","volume":"1770","author":"EM Isin","year":"2007","unstructured":"Isin, E. M. & Guengerich, F. P. Complex reactions catalyzed by cytochrome P450 enzymes. Biochim. Biophys. Acta 1770, 314\u2013329 (2007).","journal-title":"Biochim. Biophys. Acta"},{"key":"1202_CR45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/jox11030007","volume":"11","author":"F Esteves","year":"2021","unstructured":"Esteves, F., Rueff, J. & Kranendonk, M. The central role of cytochrome p450 in xenobiotic metabolism \u2014 a brief review on a fascinating enzyme family. J. Xenobiot. 11, 94\u2013114 (2021).","journal-title":"J. Xenobiot."},{"key":"1202_CR46","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fphar.2017.00417","volume":"8","author":"T Re\u017een","year":"2017","unstructured":"Re\u017een, T. et al. Evaluation of selected CYP51A1 polymorphisms in view of interactions with substrate and redox partner. Front. Pharmacol. 8, 417 (2017).","journal-title":"Front. Pharmacol."},{"key":"1202_CR47","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jsbmb.2011.06.011","volume":"127","author":"L Zou","year":"2011","unstructured":"Zou, L., Li, L. & Porter, T. D. 7-Dehydrocholesterol reductase activity is independent of cytochrome P450 reductase. J. Steroid Biochem. Mol. Biol. 127, 435\u2013438 (2011).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"1202_CR48","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3945\/an.113.005181","volume":"5","author":"JT Pinto","year":"2014","unstructured":"Pinto, J. T. & Cooper, A. J. L. From cholesterogenesis to steroidogenesis: role of riboflavin and flavoenzymes in the biosynthesis of vitamin D. Adv. Nutr. 5, 144\u2013163 (2014).","journal-title":"Adv. Nutr."},{"key":"1202_CR49","doi-asserted-by":"crossref","unstructured":"Acconcia, F. & Marino, M. in Principles of Endocrinology and Hormone Action (eds Belfiore, A & LeRoith, D.) 1\u201331 (Springer, 2016).","DOI":"10.1007\/978-3-319-27318-1_4-1"},{"key":"1202_CR50","doi-asserted-by":"publisher","first-page":"111261","DOI":"10.1016\/j.mce.2021.111261","volume":"528","author":"SD Burris-Hiday","year":"2021","unstructured":"Burris-Hiday, S. D. & Scott, E. E. Steroidogenic cytochrome P450 17A1 structure and function. Mol. Cell. Endocrinol. 528, 111261 (2021).","journal-title":"Mol. Cell. Endocrinol."},{"key":"1202_CR51","doi-asserted-by":"publisher","first-page":"591819","DOI":"10.3389\/fendo.2020.591819","volume":"11","author":"AA Hajeyah","year":"2020","unstructured":"Hajeyah, A. A., Griffiths, W. J., Wang, Y., Finch, A. J. & O\u2019Donnell, V. B. The biosynthesis of enzymatically oxidized lipids. Front. Endocrinol. 11, 591819 (2020).","journal-title":"Front. Endocrinol."},{"key":"1202_CR52","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1124\/jpet.114.216796","volume":"351","author":"X Cheng","year":"2014","unstructured":"Cheng, X., Zhang, Y. & Klaassen, C. D. Decreased bile-acid synthesis in livers of hepatocyte-conditional NADPH\u2013cytochrome P450 reductase-null mice results in increased bile acids in serum. J. Pharmacol. Exp. Therapeutics 351, 105\u2013113 (2014).","journal-title":"J. Pharmacol. Exp. Therapeutics"},{"key":"1202_CR53","doi-asserted-by":"publisher","first-page":"102344","DOI":"10.1016\/j.jbc.2022.102344","volume":"298","author":"J Liu","year":"2022","unstructured":"Liu, J., Carlson, H. A. & Scott, E. E. The structure and characterization of human cytochrome P450 8B1 supports future drug design for nonalcoholic fatty liver disease and diabetes. J. Biol. Chem. 298, 102344 (2022).","journal-title":"J. Biol. Chem."},{"key":"1202_CR54","doi-asserted-by":"publisher","first-page":"769703","DOI":"10.3389\/fphar.2021.769703","volume":"12","author":"T Heintze","year":"2021","unstructured":"Heintze, T. et al. Effects of diminished NADPH:cytochrome P450 reductase in human hepatocytes on lipid and bile acid homeostasis. Front. Pharmacol. 12, 769703 (2021).","journal-title":"Front. Pharmacol."},{"key":"1202_CR55","doi-asserted-by":"publisher","first-page":"984174","DOI":"10.3389\/fpls.2022.984174","volume":"13","author":"C-J Liu","year":"2022","unstructured":"Liu, C.-J. Cytochrome b5: a versatile electron carrier and regulator for plant metabolism. Front. Plant. Sci. 13, 984174 (2022).","journal-title":"Front. Plant. Sci."},{"key":"1202_CR56","doi-asserted-by":"publisher","first-page":"16006","DOI":"10.1038\/npjamd.2016.6","volume":"2","author":"A Martin-Montalvo","year":"2016","unstructured":"Martin-Montalvo, A. et al. Cytochrome b5 reductase and the control of lipid metabolism and healthspan. npj Aging Mech. Dis. 2, 16006 (2016).","journal-title":"npj Aging Mech. Dis."},{"key":"1202_CR57","doi-asserted-by":"publisher","first-page":"T37","DOI":"10.1530\/JME-22-0082","volume":"69","author":"LJ Gudas","year":"2022","unstructured":"Gudas, L. J. Retinoid metabolism: new insights. J. Mol. Endocrinol. 69, T37\u2013T49 (2022).","journal-title":"J. Mol. Endocrinol."},{"key":"1202_CR58","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/jdb8010006","volume":"8","author":"C Roberts","year":"2020","unstructured":"Roberts, C. Regulating retinoic acid availability during development and regeneration: the role of the CYP26 enzymes. J. Dev. Biol. 8, 6 (2020).","journal-title":"J. Dev. Biol."},{"key":"1202_CR59","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3390\/antiox9080673","volume":"9","author":"M Sugishima","year":"2020","unstructured":"Sugishima, M. et al. Conformational equilibrium of NADPH\u2013cytochrome P450 oxidoreductase is essential for heme oxygenase reaction. Antioxidants 9, 673 (2020).","journal-title":"Antioxidants"},{"key":"1202_CR60","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.abb.2011.06.008","volume":"513","author":"CC Marohnic","year":"2011","unstructured":"Marohnic, C. C. et al. Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization. Arch. Biochem. Biophys. 513, 42\u201350 (2011).","journal-title":"Arch. Biochem. Biophys."},{"key":"1202_CR61","doi-asserted-by":"publisher","first-page":"29836","DOI":"10.1074\/jbc.M114.582783","volume":"289","author":"ALM Spencer","year":"2014","unstructured":"Spencer, A. L. M., Bagai, I., Becker, D. F., Zuiderweg, E. R. P. & Ragsdale, S. W. Protein\/protein interactions in the mammalian heme degradation pathway. J. Biol. Chem. 289, 29836\u201329858 (2014).","journal-title":"J. Biol. Chem."},{"key":"1202_CR62","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/biom11040589","volume":"11","author":"V Consoli","year":"2021","unstructured":"Consoli, V., Sorrenti, V., Grosso, S. & Vanella, L. Heme oxygenase-1 signaling and redox homeostasis in physiopathological conditions. Biomolecules 11, 589 (2021).","journal-title":"Biomolecules"},{"key":"1202_CR63","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3390\/antiox11030555","volume":"11","author":"SW Ryter","year":"2022","unstructured":"Ryter, S. W. Heme oxygenase-1: an anti-inflammatory effector in cardiovascular, lung, and related metabolic disorders. Antioxidants 11, 555 (2022).","journal-title":"Antioxidants"},{"key":"1202_CR64","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908\u2013922 (2018).","journal-title":"Nat. Med."},{"key":"1202_CR65","doi-asserted-by":"crossref","unstructured":"Ferolla, S. M. in Obesity: A Practical Guide 1st edn (eds Ahmad, S. I. & Imam, S. K.) 159\u2013179 (Springer, 2016).","DOI":"10.1007\/978-3-319-19821-7_13"},{"key":"1202_CR66","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.numecd.2023.05.018","volume":"33","author":"M Wang","year":"2023","unstructured":"Wang, M. et al. The bidirectional relationship between NAFLD and type 2 diabetes: a prospective population-based cohort study. Nutrition Metab. Cardiovasc. Dis. 33, 1521\u20131528 (2023).","journal-title":"Nutrition Metab. Cardiovasc. Dis."},{"key":"1202_CR67","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi, Z. et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology 69, 2672\u20132682 (2019).","journal-title":"Hepatology"},{"key":"1202_CR68","doi-asserted-by":"publisher","first-page":"78","DOI":"10.14218\/JCTH.2014.00037","volume":"3","author":"QQ Zhang","year":"2015","unstructured":"Zhang, Q. Q. & Lu, L. G. Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy. J. Clin. Transl. Hepatol. 3, 78\u201384 (2015).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"1202_CR69","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.jhep.2021.01.019","volume":"74","author":"P Kasper","year":"2021","unstructured":"Kasper, P., Martin, A., Lang, S., Demir, M. & Steffen, H.-M. Hypertension in NAFLD: an uncontrolled burden. J. Hepatol. 74, 1258\u20131260 (2021).","journal-title":"J. Hepatol."},{"key":"1202_CR70","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1161\/CIRCRESAHA.125.325492","volume":"136","author":"F Capone","year":"2025","unstructured":"Capone, F. et al. Decoding the liver\u2013heart axis in cardiometabolic diseases. Circ. Res. 136, 1335\u20131362 (2025).","journal-title":"Circ. Res."},{"key":"1202_CR71","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1161\/HYPERTENSIONAHA.121.18752","volume":"79","author":"PF Malacarne","year":"2022","unstructured":"Malacarne, P. F. et al. Loss of endothelial cytochrome P450 reductase induces vascular dysfunction in mice. Hypertension 79, 1216\u20131226 (2022).","journal-title":"Hypertension"},{"key":"1202_CR72","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1096\/fj.10-160119","volume":"24","author":"CR Lee","year":"2010","unstructured":"Lee, C. R. et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 24, 3770\u20133781 (2010).","journal-title":"FASEB J."},{"key":"1202_CR73","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1053\/j.gastro.2020.08.001","volume":"159","author":"A Arvind","year":"2020","unstructured":"Arvind, A., Osganian, S. A., Sjoquist, J. A., Corey, K. E. & Simon, T. G. Epoxygenase-derived epoxyeicosatrienoic acid mediators are associated with nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and fibrosis. Gastroenterology 159, 2232\u20132234 (2020).","journal-title":"Gastroenterology"},{"key":"1202_CR74","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1124\/jpet.107.130336","volume":"324","author":"T Ishizuka","year":"2008","unstructured":"Ishizuka, T. et al. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-\u03baB activation and the production of inflammatory cytokines in human endothelial cells. J. Pharmacol. Exp. Ther. 324, 103\u2013110 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1202_CR75","doi-asserted-by":"publisher","first-page":"115242","DOI":"10.1016\/j.bcp.2022.115242","volume":"205","author":"C Ma","year":"2022","unstructured":"Ma, C., Han, L., Zhu, Z., Heng Pang, C. & Pan, G. Mineral metabolism and ferroptosis in non-alcoholic fatty liver diseases. Biochem. Pharmacol. 205, 115242 (2022).","journal-title":"Biochem. Pharmacol."},{"key":"1202_CR76","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","volume":"10","author":"A Wree","year":"2013","unstructured":"Wree, A., Broderick, L., Canbay, A., Hoffman, H. M. & Feldstein, A. E. From NAFLD to NASH to cirrhosis \u2014 new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10, 627\u2013636 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1202_CR77","doi-asserted-by":"publisher","first-page":"692","DOI":"10.2174\/138920009789895543","volume":"10","author":"M Jos\u00e9 G\u00f3mez-Lech\u00f3n","year":"2009","unstructured":"Jos\u00e9 G\u00f3mez-Lech\u00f3n, M., Jover, R. & Donato, M. T. Cytochrome P450 and steatosis. Curr. Drug Metab. 10, 692\u2013699 (2009).","journal-title":"Curr. Drug Metab."},{"key":"1202_CR78","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","volume":"76","author":"F Bessone","year":"2019","unstructured":"Bessone, F., Razori, M. V. & Roma, M. G. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell. Mol. Life Sci. 76, 99\u2013128 (2019).","journal-title":"Cell. Mol. Life Sci."},{"key":"1202_CR79","doi-asserted-by":"publisher","first-page":"113374","DOI":"10.1016\/j.biopha.2022.113374","volume":"153","author":"S Wang","year":"2022","unstructured":"Wang, S., Liu, Z., Geng, J., Li, L. & Feng, X. An overview of ferroptosis in non-alcoholic fatty liver disease. Biomed. Pharmacother. 153, 113374 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"1202_CR80","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/metabo14070366","volume":"14","author":"NG Vallianou","year":"2024","unstructured":"Vallianou, N. G. et al. NAFLD\/MASLD and the gut\u2013liver axis: from pathogenesis to treatment options. Metabolites 14, 366 (2024).","journal-title":"Metabolites"},{"key":"1202_CR81","doi-asserted-by":"publisher","first-page":"770986","DOI":"10.3389\/fendo.2021.770986","volume":"12","author":"T Kessoku","year":"2021","unstructured":"Kessoku, T. et al. Endotoxins and non-alcoholic fatty liver disease. Front. Endocrinol. 12, 770986 (2021).","journal-title":"Front. Endocrinol."},{"key":"1202_CR82","doi-asserted-by":"publisher","first-page":"1639646","DOI":"10.3389\/fphar.2025.1639646","volume":"16","author":"H Ali","year":"2025","unstructured":"Ali, H. et al. The impact of the exposome on cytochrome P450-mediated drug metabolism. Front. Pharmacol. 16, 1639646 (2025).","journal-title":"Front. Pharmacol."},{"key":"1202_CR83","first-page":"579","volume":"17","author":"KF Sweeny","year":"2021","unstructured":"Sweeny, K. F. & Lee, C. K. Nonalcoholic fatty liver disease in children. Gastroenterol. Hepatol. 17, 579\u2013587 (2021).","journal-title":"Gastroenterol. Hepatol."},{"key":"1202_CR84","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","volume":"23","author":"BJ Perumpail","year":"2017","unstructured":"Perumpail, B. J. et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J. Gastroenterol. 23, 8263\u20138276 (2017).","journal-title":"World J. Gastroenterol."},{"key":"1202_CR85","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/CIA.S295524","volume":"16","author":"SA Alqahtani","year":"2021","unstructured":"Alqahtani, S. A. & Schattenberg, J. M. NAFLD in the elderly. Clin. Interv. Aging 16, 1633\u20131649 (2021).","journal-title":"Clin. Interv. Aging"},{"key":"1202_CR86","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam, M., Valenti, L. & Romeo, S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J. Hepatol. 68, 268\u2013279 (2018).","journal-title":"J. Hepatol."},{"key":"1202_CR87","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti, E., Pinzani, M. & Tsochatzis, E. A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65, 1038\u20131048 (2016).","journal-title":"Metabolism"},{"key":"1202_CR88","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.3350\/cmh.2022.0398","volume":"29","author":"E Ko","year":"2023","unstructured":"Ko, E., Yoon, E. L. & Jun, D. W. Risk factors in nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29, S79\u2013S85 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"1202_CR89","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013478","volume":"97","author":"Y Liu","year":"2018","unstructured":"Liu, Y., Li, P., Liu, L. & Zhang, Y. The diagnostic role of miR-122 in drug-induced liver injury. Medicine 97, e13478 (2018).","journal-title":"Medicine"},{"key":"1202_CR90","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14737159.2018.1415145","volume":"18","author":"LS Howell","year":"2018","unstructured":"Howell, L. S., Ireland, L., Park, B. K. & Goldring, C. E. MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury. Expert Rev. Mol. Diagn. 18, 47\u201354 (2018).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"1202_CR91","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1016\/j.ajpath.2017.08.026","volume":"187","author":"V Chowdhary","year":"2017","unstructured":"Chowdhary, V. et al. miRNA-122 protects mice and human hepatocytes from acetaminophen toxicity by regulating cytochrome p450 family 1 subfamily a member 2 and family 2 subfamily e member 1 expression. Am. J. Pathol. 187, 2758\u20132774 (2017).","journal-title":"Am. J. Pathol."},{"key":"1202_CR92","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s13105-024-01037-8","volume":"81","author":"AL Tobaruela-Resola","year":"2024","unstructured":"Tobaruela-Resola, A. L. et al. Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for metabolic dysfunction-associated steatotic liver disease assessment. J. Physiol. Biochem. 81, 1275\u20131288 (2024).","journal-title":"J. Physiol. Biochem."},{"key":"1202_CR93","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41416-025-02969-8","volume":"132","author":"H-Y Lin","year":"2025","unstructured":"Lin, H.-Y. et al. The epigenetic basis of hepatocellular carcinoma \u2014 mechanisms and potential directions for biomarkers and therapeutics. Br. J. Cancer 132, 869\u2013887 (2025).","journal-title":"Br. J. Cancer"},{"key":"1202_CR94","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/apt.14952","volume":"48","author":"F Bessone","year":"2018","unstructured":"Bessone, F., Dirchwolf, M., Rodil, M. A., Razori, M. V. & Roma, M. G. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease \u2014 a physiopathological and clinical integrated view. Aliment. Pharmacol. Ther. 48, 892\u2013913 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1202_CR95","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.3390\/ijms25105203","volume":"25","author":"E L\u00f3pez-Pascual","year":"2024","unstructured":"L\u00f3pez-Pascual, E. et al. Drug-induced fatty liver disease (DIFLD): a comprehensive analysis of clinical, biochemical, and histopathological data for mechanisms identification and consistency with current adverse outcome pathways. Int. J. Mol. Sci. 25, 5203 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1202_CR96","doi-asserted-by":"publisher","DOI":"10.24018\/ejmed.2020.2.4.439","author":"G Bokan","year":"2020","unstructured":"Bokan, G., Male\u0161evi\u0107, N., Licata, A. & Mavija, Z. Drug Induced Liver Injury (Dili) and non alcoholic fatty liver disease (NAFLD). Eur. J. Med. Health Sci. https:\/\/doi.org\/10.24018\/ejmed.2020.2.4.439 (2020).","journal-title":"Eur. J. Med. Health Sci."},{"key":"1202_CR97","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/ijms23031062","volume":"23","author":"J Massart","year":"2022","unstructured":"Massart, J., Begriche, K., Corlu, A. & Fromenty, B. Xenobiotic-induced aggravation of metabolic-associated fatty liver disease. Int. J. Mol. Sci. 23, 1062 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1202_CR98","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cgh.2024.01.006","volume":"22","author":"P Nasr","year":"2024","unstructured":"Nasr, P. et al. Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis. Clin. Gastroenterol. Hepatol. 22, 1048\u20131057 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1202_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44355-024-00014-8","volume":"2","author":"H Leal-Lassalle","year":"2025","unstructured":"Leal-Lassalle, H., Est\u00e9vez-V\u00e1zquez, O., Cubero, F. J. & Nevzorova, Y. A. Metabolic and alcohol-associated liver disease (MetALD): a representation of duality. npj Gut Liver 2, 1\u201311 (2025).","journal-title":"npj Gut Liver"},{"key":"1202_CR100","doi-asserted-by":"crossref","unstructured":"Ota, T. in Advances in Experimental Medicine and Biology (ed. Misawa, N.) Vol. 1261, 223\u2013229 (Springer, 2021).","DOI":"10.1007\/978-981-15-7360-6_20"},{"key":"1202_CR101","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/FPC.0b013e3282f2f121","volume":"18","author":"SN Hart","year":"2008","unstructured":"Hart, S. N. et al. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet. Genomics 18, 11\u201324 (2008).","journal-title":"Pharmacogenet. Genomics"},{"key":"1202_CR102","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.apsb.2022.08.005","volume":"13","author":"J Lu","year":"2023","unstructured":"Lu, J. et al. The role of CYP1A1\/2 in cholesterol ester accumulation provides a new perspective for the treatment of hypercholesterolemia. Acta Pharm. Sin. B 13, 648\u2013661 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"1202_CR103","doi-asserted-by":"publisher","first-page":"119648","DOI":"10.1016\/j.lfs.2021.119648","volume":"278","author":"TTH Dang","year":"2021","unstructured":"Dang, T. T. H. & Yun, J. W. Cytochrome P450 2E1 (CYP2E1) positively regulates lipid catabolism and induces browning in 3T3-L1 white adipocytes. Life Sci. 278, 119648 (2021).","journal-title":"Life Sci."},{"key":"1202_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines10112686","volume":"10","author":"LS Klyushova","year":"2022","unstructured":"Klyushova, L. S., Perepechaeva, M. L. & Grishanova, A. Y. The role of CYP3A in health and disease. Biomedicines 10, 1\u201356 (2022).","journal-title":"Biomedicines"},{"key":"1202_CR105","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.livres.2020.05.001","volume":"4","author":"JYL Chiang","year":"2020","unstructured":"Chiang, J. Y. L. & Ferrell, J. M. Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis. Liver Res. 4, 47\u201363 (2020).","journal-title":"Liver Res."},{"key":"1202_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/ceh.2021.104441","volume":"7","author":"N Wasilewska","year":"2021","unstructured":"Wasilewska, N. & Lebensztejn, D. M. Non-alcoholic fatty liver disease and lipotoxicity. Clin. Exp. Hepatol. 7, 1\u20136 (2021).","journal-title":"Clin. Exp. Hepatol."},{"key":"1202_CR107","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12072-020-10121-2","volume":"15","author":"Y Geng","year":"2021","unstructured":"Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H. & Moshage, H. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol. Int. 15, 21\u201335 (2021).","journal-title":"Hepatol. Int."},{"key":"1202_CR108","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s44324-025-00058-1","volume":"3","author":"F Gachon","year":"2025","unstructured":"Gachon, F. et al. Potential bidirectional communication between the liver and the central circadian clock in MASLD. npj Metab. Health Dis. 3, 15 (2025).","journal-title":"npj Metab. Health Dis."},{"key":"1202_CR109","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jhep.2014.11.002","volume":"62","author":"K Anjani","year":"2015","unstructured":"Anjani, K. et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. J. Hepatol. 62, 905\u2013912 (2015).","journal-title":"J. Hepatol."},{"key":"1202_CR110","doi-asserted-by":"publisher","first-page":"G75","DOI":"10.1152\/ajpgi.00170.2018","volume":"316","author":"S Liangpunsakul","year":"2019","unstructured":"Liangpunsakul, S. & Chalasani, N. Lipid mediators of liver injury in nonalcoholic fatty liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 316, G75\u2013G81 (2019).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1202_CR111","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2217\/clp.09.85","volume":"5","author":"SC Cazanave","year":"2010","unstructured":"Cazanave, S. C. & Gores, G. J. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin. Lipidol. 5, 71\u201385 (2010).","journal-title":"Clin. Lipidol."},{"key":"1202_CR112","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cotox.2017.10.003","volume":"7","author":"A Veith","year":"2018","unstructured":"Veith, A. & Moorthy, B. Role of cytochrome P450s in the generation and metabolism of reactive oxygen species. Curr. Opin. Toxicol. 7, 44\u201351 (2018).","journal-title":"Curr. Opin. Toxicol."},{"key":"1202_CR113","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","volume":"152","author":"Z Chen","year":"2020","unstructured":"Chen, Z., Tian, R., She, Z., Cai, J. & Li, H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free. Radic. Biol. Med. 152, 116\u2013141 (2020).","journal-title":"Free. Radic. Biol. Med."},{"key":"1202_CR114","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/antiox10020174","volume":"10","author":"JC Arroyave-Ospina","year":"2021","unstructured":"Arroyave-Ospina, J. C., Wu, Z., Geng, Y. & Moshage, H. Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: implications for prevention and therapy. Antioxidants 10, 174 (2021).","journal-title":"Antioxidants"},{"key":"1202_CR115","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1210\/jc.2006-0587","volume":"91","author":"KM Utzschneider","year":"2006","unstructured":"Utzschneider, K. M. & Kahn, S. E. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 91, 4753\u20134761 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1202_CR116","doi-asserted-by":"publisher","first-page":"595371","DOI":"10.3389\/fmed.2021.595371","volume":"8","author":"AP Delli Bovi","year":"2021","unstructured":"Delli Bovi, A. P. et al. Oxidative stress in non-alcoholic fatty liver disease. an updated mini review. Front. Med. 8, 595371 (2021).","journal-title":"Front. Med."},{"key":"1202_CR117","doi-asserted-by":"publisher","first-page":"107400","DOI":"10.1016\/j.pharmthera.2019.107400","volume":"204","author":"N Isoherranen","year":"2019","unstructured":"Isoherranen, N. & Zhong, G. Biochemical and physiological importance of the CYP26 retinoic acid hydroxylases. Pharmacol. Ther. 204, 107400 (2019).","journal-title":"Pharmacol. Ther."},{"key":"1202_CR118","doi-asserted-by":"crossref","unstructured":"Stevison, F., Jing, J., Tripathy, S. & Isoherranen, N. in Advances in Pharmacology Vol. 74 (ed. Hardwick, J. P.) Ch. 11, 373\u2013412 (Elsevier, 2015).","DOI":"10.1016\/bs.apha.2015.04.006"},{"key":"1202_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110162","volume":"9","author":"RN Schuck","year":"2014","unstructured":"Schuck, R. N. et al. The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. PLoS ONE 9, e110162 (2014).","journal-title":"PLoS ONE"},{"key":"1202_CR120","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/cells11020288","volume":"11","author":"J Massart","year":"2022","unstructured":"Massart, J., Begriche, K., Hartman, J. H. & Fromenty, B. Role of mitochondrial cytochrome P450 2E1 in healthy and diseased liver. Cells 11, 288 (2022).","journal-title":"Cells"},{"key":"1202_CR121","doi-asserted-by":"publisher","first-page":"12627","DOI":"10.1074\/jbc.M113.452367","volume":"288","author":"S Bansal","year":"2013","unstructured":"Bansal, S. et al. Human cytochrome P450 2E1 mutations that alter mitochondrial targeting efficiency and susceptibility to ethanol-induced toxicity in cellular models. J. Biol. Chem. 288, 12627\u201312644 (2013).","journal-title":"J. Biol. Chem."},{"key":"1202_CR122","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1155\/2014\/757929","volume":"28","author":"MG Neuman","year":"2014","unstructured":"Neuman, M. G., Cohen, L. B. & Nanau Bsc, R. M. Biomarkers in nonalcoholic fatty liver disease. Can. J. Gastroenterol. Hepatol. 28, 607\u2013620 (2014).","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"1202_CR123","doi-asserted-by":"crossref","unstructured":"Cederbaum, A. I. in Advances in Bioactivation Research (ed. Elfarra, A.) Vol. 9, 1\u201336 (Springer, 2008).","DOI":"10.1007\/978-0-387-77300-1_6"},{"key":"1202_CR124","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/1874467208666150817111114","volume":"10","author":"MA Abdelmegeed","year":"2017","unstructured":"Abdelmegeed, M. A., Ha, S.-K., Choi, Y., Akbar, M. & Song, B.-J. Role of CYP2E1 in mitochondrial dysfunction and hepatic injury by alcohol and non-alcoholic substances. Curr. Mol. Pharmacol. 10, 207\u2013225 (2017).","journal-title":"Curr. Mol. Pharmacol."},{"key":"1202_CR125","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41374-021-00610-9","volume":"101","author":"T Xun","year":"2021","unstructured":"Xun, T. et al. Advanced oxidation protein products downregulate CYP1A2 and CYP3A4 expression and activity via the NF-\u03baB-mediated signaling pathway in vitro and in vivo. Lab. Invest. 101, 1197\u20131209 (2021).","journal-title":"Lab. Invest."},{"key":"1202_CR126","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1210\/clinem\/dgae815","volume":"110","author":"WL Miller","year":"2025","unstructured":"Miller, W. L., Pandey, A. V. & Fl\u00fcck, C. E. Disordered electron transfer: new forms of defective steroidogenesis and mitochondriopathy. J. Clin. Endocrinol. Metab. 110, e574\u2013e582 (2025).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1202_CR127","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1111\/j.1742-4658.2011.08357.x","volume":"278","author":"L Knockaert","year":"2011","unstructured":"Knockaert, L., Fromenty, B. & Robin, M. Mechanisms of mitochondrial targeting of cytochrome P450 2E1: physiopathological role in liver injury and obesity. FEBS J. 278, 4252\u20134260 (2011).","journal-title":"FEBS J."},{"key":"1202_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","volume":"6","author":"K Begriche","year":"2006","unstructured":"Begriche, K., Igoudjil, A., Pessayre, D. & Fromenty, B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6, 1\u201328 (2006).","journal-title":"Mitochondrion"},{"key":"1202_CR129","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/biom12060824","volume":"12","author":"F Nassir","year":"2022","unstructured":"Nassir, F. NAFLD: mechanisms, treatments, and biomarkers. Biomolecules 12, 824 (2022).","journal-title":"Biomolecules"},{"key":"1202_CR130","doi-asserted-by":"publisher","first-page":"1090338","DOI":"10.3389\/fnut.2023.1090338","volume":"10","author":"Z Cheng","year":"2023","unstructured":"Cheng, Z., Chu, H., Zhu, Q. & Yang, L. Ferroptosis in non-alcoholic liver disease: molecular mechanisms and therapeutic implications. Front. Nutr. 10, 1090338 (2023).","journal-title":"Front. Nutr."},{"key":"1202_CR131","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3390\/ijms21051651","volume":"21","author":"RU Mac\u00edas-Rodr\u00edguez","year":"2020","unstructured":"Mac\u00edas-Rodr\u00edguez, R. U. et al. Reclassifying hepatic cell death during liver damage: ferroptosis \u2014 a novel form of non-apoptotic cell death? Int. J. Mol. Sci. 21, 1651 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1202_CR132","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.3390\/biomedicines9111660","volume":"9","author":"H Zhang","year":"2021","unstructured":"Zhang, H., Zhang, E. & Hu, H. Role of ferroptosis in non-alcoholic fatty liver disease and its implications for therapeutic strategies. Biomedicines 9, 1660 (2021).","journal-title":"Biomedicines"},{"key":"1202_CR133","doi-asserted-by":"publisher","first-page":"801365","DOI":"10.3389\/fcell.2021.801365","volume":"9","author":"S Chen","year":"2021","unstructured":"Chen, S., Zhu, J., Zang, X. & Zhai, Y. The emerging role of ferroptosis in liver diseases. Front. Cell Dev. Biol. 9, 801365 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1202_CR134","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41420-021-00660-4","volume":"7","author":"J Wu","year":"2021","unstructured":"Wu, J. et al. Ferroptosis in liver disease: new insights into disease mechanisms. Cell Death Discov. 7, 276 (2021).","journal-title":"Cell Death Discov."},{"key":"1202_CR135","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molcel.2020.11.024","volume":"81","author":"B Yan","year":"2021","unstructured":"Yan, B. et al. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Mol. Cell 81, 355\u2013369 (2021).","journal-title":"Mol. Cell"},{"key":"1202_CR136","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.3390\/cells10092401","volume":"10","author":"S-K Chiang","year":"2021","unstructured":"Chiang, S.-K., Chen, S.-E. & Chang, L.-C. The role of HO-1 and its crosstalk with oxidative stress in cancer cell survival. Cells 10, 2401 (2021).","journal-title":"Cells"},{"key":"1202_CR137","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1182\/blood.V100.3.879","volume":"100","author":"V Jeney","year":"2002","unstructured":"Jeney, V. et al. Pro-oxidant and cytotoxic effects of circulating heme. Blood 100, 879\u2013887 (2002).","journal-title":"Blood"},{"key":"1202_CR138","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","volume":"285","author":"K Node","year":"1999","unstructured":"Node, K. et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276\u20131279 (1999).","journal-title":"Science"},{"key":"1202_CR139","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41423-025-01313-7","volume":"22","author":"E Kostallari","year":"2025","unstructured":"Kostallari, E., Schwabe, R. F. & Guillot, A. Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells. Cell. Mol. Immunol. 22, 1205\u20131225 (2025).","journal-title":"Cell. Mol. Immunol."},{"key":"1202_CR140","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3390\/antiox12091653","volume":"12","author":"A Allameh","year":"2023","unstructured":"Allameh, A., Niayesh-Mehr, R., Aliarab, A., Sebastiani, G. & Pantopoulos, K. Oxidative stress in liver pathophysiology and disease. Antioxidants 12, 1653 (2023).","journal-title":"Antioxidants"},{"key":"1202_CR141","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/hep.510300433","volume":"30","author":"N Nieto","year":"1999","unstructured":"Nieto, N., Friedman, S. L., Greenwel, P. & Cederbaum, A. I. CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology 30, 987\u2013996 (1999).","journal-title":"Hepatology"},{"key":"1202_CR142","doi-asserted-by":"publisher","first-page":"809952","DOI":"10.3389\/fcell.2021.809952","volume":"9","author":"W Gao","year":"2022","unstructured":"Gao, W. et al. Dissecting the crosstalk between Nrf2 and NF-\u03baB response pathways in drug-induced toxicity. Front. Cell Dev. Biol. 9, 809952 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"1202_CR143","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu, T., Zhang, L., Joo, D. & Sun, S.-C. NF-\u03baB signaling in inflammation. Signal Transduct. Target. Ther. 2, 17023 (2017).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1202_CR144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290532","volume":"18","author":"H-Y Seo","year":"2023","unstructured":"Seo, H.-Y. et al. Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver. PLoS ONE 18, e0290532 (2023).","journal-title":"PLoS ONE"},{"key":"1202_CR145","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/humu.24309","volume":"43","author":"S Gudmundsson","year":"2022","unstructured":"Gudmundsson, S. et al. Variant interpretation using population databases: lessons from gnomAD. Hum. Mutat. 43, 1012\u20131030 (2022).","journal-title":"Hum. Mutat."},{"key":"1202_CR146","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/biom13071083","volume":"13","author":"F Esteves","year":"2023","unstructured":"Esteves, F. et al. Single mutations in cytochrome P450 oxidoreductase can alter the specificity of human cytochrome P450 1A2-mediated caffeine metabolism. Biomolecules 13, 1083 (2023).","journal-title":"Biomolecules"},{"key":"1202_CR147","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bbrc.2019.05.127","volume":"515","author":"MNR Velazquez","year":"2019","unstructured":"Velazquez, M. N. R., Parween, S., Udhane, S. S. & Pandey, A. V. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase. Biochem. Biophys. Res. Commun. 515, 133\u2013138 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1202_CR148","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/ajmg.a.30169","volume":"128A","author":"M Adachi","year":"2004","unstructured":"Adachi, M. et al. Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley\u2013Bixler syndrome. Am. J. Med. Genet. A 128A, 333\u2013339 (2004).","journal-title":"Am. J. Med. Genet. A"},{"key":"1202_CR149","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ped4.12035","volume":"2","author":"C Hao","year":"2018","unstructured":"Hao, C. et al. Compound heterozygous variants in POR gene identified by whole-exome sequencing in a Chinese pedigree with cytochrome P450 oxidoreductase deficiency. Pediatr. Investig. 2, 90\u201395 (2018).","journal-title":"Pediatr. Investig."},{"key":"1202_CR150","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/ped.12518","volume":"56","author":"M Fukami","year":"2014","unstructured":"Fukami, M. & Ogata, T. Cytochrome P450 oxidoreductase deficiency: rare congenital disorder leading to skeletal malformations and steroidogenic defects. Pediatrics Int. 56, 805\u2013808 (2014).","journal-title":"Pediatrics Int."},{"key":"1202_CR151","doi-asserted-by":"publisher","first-page":"1226387","DOI":"10.3389\/fendo.2023.1226387","volume":"14","author":"C Wang","year":"2023","unstructured":"Wang, C. & Tian, Q. Diagnostic challenges and management advances in cytochrome P450 oxidoreductase deficiency, a rare form of congenital adrenal hyperplasia, with 46, XX karyotype. Front. Endocrinol. 14, 1226387 (2023).","journal-title":"Front. Endocrinol."},{"key":"1202_CR152","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1086\/429417","volume":"76","author":"N Huang","year":"2005","unstructured":"Huang, N. et al. Diversity and function of mutations in P450 oxidoreductase in patients with Antley\u2013Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 76, 729\u2013749 (2005).","journal-title":"Am. J. Hum. Genet."},{"key":"1202_CR153","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.mce.2008.09.017","volume":"300","author":"WL Miller","year":"2009","unstructured":"Miller, W. L., Huang, N., Agrawal, V. & Giacomini, K. M. Genetic variation in human P450 oxidoreductase. Mol. Cell. Endocrinol. 300, 180\u2013184 (2009).","journal-title":"Mol. Cell. Endocrinol."},{"key":"1202_CR154","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1073\/pnas.0711621105","volume":"105","author":"N Huang","year":"2008","unstructured":"Huang, N., Agrawal, V., Giacomini, K. M. & Miller, W. L. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc. Natl Acad. Sci. USA 105, 1733\u20131738 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1202_CR155","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.3390\/biom13121728","volume":"13","author":"MN Rojas Velazquez","year":"2023","unstructured":"Rojas Velazquez, M. N., Therkelsen, S. & Pandey, A. V. Exploring novel variants of the cytochrome P450 reductase gene (POR) from the Genome Aggregation Database by integrating bioinformatic tools and functional assays. Biomolecules 13, 1728 (2023).","journal-title":"Biomolecules"},{"key":"1202_CR156","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1202_CR157","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1210\/me.2010-0236","volume":"25","author":"MK Tee","year":"2011","unstructured":"Tee, M. K., Huang, N., Damm, I. & Miller, W. L. Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms. Mol. Endocrinol. 25, 715\u2013731 (2011).","journal-title":"Mol. Endocrinol."},{"key":"1202_CR158","doi-asserted-by":"publisher","first-page":"18757","DOI":"10.1073\/pnas.1421708111","volume":"111","author":"BP Johnson","year":"2014","unstructured":"Johnson, B. P. et al. Hepatocyte circadian clock controls acetaminophen bioactivation through NADPH\u2013cytochrome P450 oxidoreductase. Proc. Natl Acad. Sci. USA 111, 18757\u201318762 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1202_CR159","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/acer.12209","volume":"38","author":"X Dong","year":"2014","unstructured":"Dong, X., Liu, H., Chen, F., Li, D. & Zhao, Y. MiR-214 promotes the alcohol-induced oxidative stress via down-regulation of glutathione reductase and cytochrome P450 oxidoreductase in liver cells. Alcohol Clin. Exp. Res. 38, 68\u201377 (2014).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"1202_CR160","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1053\/j.gastro.2013.07.047","volume":"145","author":"SK Murphy","year":"2013","unstructured":"Murphy, S. K. et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology 145, 1076\u20131087 (2013).","journal-title":"Gastroenterology"},{"key":"1202_CR161","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/ijms19030911","volume":"19","author":"J Del Campo","year":"2018","unstructured":"Del Campo, J., Gallego-Dur\u00e1n, R., Gallego, P. & Grande, L. Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD). Int. J. Mol. Sci. 19, 9\u201311 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1202_CR162","first-page":"608","volume":"81","author":"C da Ismael","year":"2022","unstructured":"da Ismael, C. et al. Dysregulation of cytochrome P450 oxidoreductase (POR) in NAFLD and hepatocellular carcinoma; evidence from clinical, rodent and cellular models. Endocr. Abstr. 81, 608\u2013608 (2022).","journal-title":"Endocr. Abstr."},{"key":"1202_CR163","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1053\/j.gastro.2020.12.023","volume":"160","author":"O Jamialahmadi","year":"2021","unstructured":"Jamialahmadi, O. et al. Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease. Gastroenterology 160, 1634\u20131646 (2021).","journal-title":"Gastroenterology"},{"key":"1202_CR164","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","volume":"73","author":"QM Anstee","year":"2020","unstructured":"Anstee, Q. M. et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J. Hepatol. 73, 505\u2013515 (2020).","journal-title":"J. Hepatol."},{"key":"1202_CR165","doi-asserted-by":"crossref","unstructured":"Guengerich, F. P. in Cytochrome P450 (ed. Ortiz de Montellano, P.) 523\u2013785 (Springer, 2015).","DOI":"10.1007\/978-3-319-12108-6_9"},{"key":"1202_CR166","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/antiox9121279","volume":"9","author":"E Ramos-Tovar","year":"2020","unstructured":"Ramos-Tovar, E. & Muriel, P. Molecular mechanisms that link oxidative stress, inflammation, and fibrosis in the liver. Antioxidants 9, 1279 (2020).","journal-title":"Antioxidants"},{"key":"1202_CR167","doi-asserted-by":"publisher","first-page":"E1881","DOI":"10.1210\/jc.2011-1337","volume":"96","author":"S Soneda","year":"2011","unstructured":"Soneda, S. et al. Proximal promoter of the cytochrome P450 oxidoreductase gene: identification of microdeletions involving the untranslated exon 1 and critical function of the SP1 binding sites. J. Clin. Endocrinol. Metab. 96, E1881\u2013E1887 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1202_CR168","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1124\/mol.52.1.46","volume":"52","author":"KA O\u2019Leary","year":"1997","unstructured":"O\u2019Leary, K. A. et al. Thyroid regulation of NADPH:cytochrome P450 oxidoreductase: identification of a thyroid-responsive element in the 5\u2032-flank of the oxidoreductase gene. Mol. Pharmacol. 52, 46\u201353 (1997).","journal-title":"Mol. Pharmacol."},{"key":"1202_CR169","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrendo.2018.10","volume":"14","author":"RA Sinha","year":"2018","unstructured":"Sinha, R. A., Singh, B. K. & Yen, P. M. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat. Rev. Endocrinol. 14, 259\u2013269 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1202_CR170","doi-asserted-by":"publisher","first-page":"100144","DOI":"10.1016\/j.endmts.2023.100144","volume":"13","author":"G Rehman","year":"2023","unstructured":"Rehman, G., Kumari, N., Bano, F. & Tyagi, R. K. Thyroid hormone receptor beta: relevance in human health and diseases. Endocr. Metab. Sci. 13, 100144 (2023).","journal-title":"Endocr. Metab. Sci."},{"key":"1202_CR171","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jsbmb.2016.04.003","volume":"165","author":"FZ Burkhard","year":"2017","unstructured":"Burkhard, F. Z., Parween, S., Udhane, S. S., Fl\u00fcck, C. E. & Pandey, A. V. P450 oxidoreductase deficiency: analysis of mutations and polymorphisms. J. Steroid Biochem. Mol. Biol. 165, 38\u201350 (2017).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"1202_CR172","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.abb.2008.04.014","volume":"475","author":"M Kranendonk","year":"2008","unstructured":"Kranendonk, M. et al. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley\u2013Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch. Biochem. Biophys. 475, 93\u201399 (2008).","journal-title":"Arch. Biochem. Biophys."},{"key":"1202_CR173","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1124\/dmd.111.042820","volume":"40","author":"D Moutinho","year":"2012","unstructured":"Moutinho, D. et al. Altered human CYP3A4 activity caused by Antley\u2013Bixler syndrome-related variants of NADPH\u2013cytochrome P450 oxidoreductase measured in a robust in vitro system. Drug Metab. Disposition 40, 754\u2013760 (2012).","journal-title":"Drug Metab. Disposition"},{"key":"1202_CR174","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3389\/fphar.2017.00580","volume":"8","author":"SS Udhane","year":"2017","unstructured":"Udhane, S. S., Parween, S., Kagawa, N. & Pandey, A. V. Altered CYP19A1 and CYP3A4 activities due to mutations a115V, T142A, Q153R and P284L in the human P450 oxidoreductase. Front. Pharmacol. 8, 580 (2017).","journal-title":"Front. Pharmacol."},{"key":"1202_CR175","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/FPC.0000000000000297","volume":"27","author":"L Gong","year":"2017","unstructured":"Gong, L., Zhang, C.-M., Lv, J.-F., Zhou, H.-H. & Fan, L. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet. Genomics 27, 337\u2013346 (2017).","journal-title":"Pharmacogenet. Genomics"}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01202-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01202-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01202-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:02:00Z","timestamp":1785240120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01202-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":175,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1038\/s41575-026-01202-y","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"25 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.J.K. serves as a consultant or advisory board member for Resolution Therapeutics, Clinnovate Health, HistoIndex, Fibrofind, Kynos Therapeutics, Perspectum, Concept Life Sciences, Servier Laboratories and Jazz Pharmaceuticals, and has received speakers\u2019 fees from Servier Laboratories, Jazz Pharmaceuticals, AstraZeneca, HistoIndex and Incyte Corporation. J.A.F. serves as a consultant or advisory board member for Resolution Therapeutics, Kynos Therapeutics, Gyre Therapeutics, Ipsen, River 2 Renal Corp., Stimuliver, Guidepoint and ICON plc, and has received speaker fees from HistoIndex, International Society for Continuing Professional Development (SICLEO) and Resolution Therapeutics and has received a research grant from GlaxoSmithKline and Genentech. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors acknowledge that papers authored by scholars from historically excluded groups are systematically under-cited. Every attempt has been made to reference relevant papers in a manner that is equitable in terms of racial, ethnic, gender and geographical representation.","order":2,"name":"Ethics","label":"Citation diversity statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}